Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (Q40816843)

24 September 2017

Reimbursement Decisions for Pharmaceuticals in Sweden: The Impact of Disease Severity and Cost Effectiveness (English)

1 reference

24 September 2017

0 references

Mikael Svensson

1

0 references

author name string

Fredrik O L Nilsson

series ordinal

2

1 reference

PubMed ID

26093889

24 September 2017

Karl Arnberg

series ordinal

3

1 reference

24 September 2017

21 June 2015

1 reference

24 September 2017

1 reference

24 September 2017

33

1 reference

24 September 2017

11

1 reference

24 September 2017

1229-1236

1 reference

https://scigraph.springernature.com/pub.10.1007/s40273-015-0307-6

24 September 2017

0 references

cites work

Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Reimbursement and clinical guidance for pharmaceuticals in Sweden: do health-economic evaluations support decision making?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Reimbursement decisions of the All Wales Medicines Strategy Group: influence of policy and clinical and economic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Value-based differential pricing: efficient prices for drugs in a global context

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

The value of a statistical life in Sweden: a review of the empirical literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Who wants to know if their care is rationed? Views of citizens and service informants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

Endogenous cost-effectiveness analysis and health care technology adoption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40273-015-0307-6

THE INFLUENCE OF COST-EFFECTIVENESS AND OTHER FACTORS ON NICE DECISIONS.

21 January 2018

1 reference

12 December 2020

“Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making

1 reference

12 December 2020

Cost-effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in australia (1991 to 1996)

1 reference

12 December 2020

A regulatory governance perspective on Health Technology Assessment (HTA) in Sweden

1 reference

12 December 2020

Decision making by NICE: examining the influences of evidence, process and context

1 reference

12 December 2020

10.1007/S40273-015-0307-6

Identifiers

DOI

1 reference

PubMed ID

26093889

Dimensions Publication ID

24 September 2017

0 references

1 reference

PubMed ID

26093889